Vanguard Group Inc. Sells 326,415 Shares of AnaptysBio, Inc. $ANAB

Key Points

• Vanguard Group Inc. has decreased its stake in AnaptysBio, Inc. by 17.7%, selling 326,415 shares and holding 1,517,325 shares afterward, valued at about $28.2 million.
• AnaptysBio reported a quarterly EPS of ($1.34), which is better than analysts' expectations of ($1.50), with revenue reaching $22.26 million compared to the anticipated $11.55 million.
• Analysts exhibit confidence in AnaptysBio, with a consensus rating of “Moderate Buy” and an average price target of $46.13 for the stock, reflecting positive sentiment in the market.

Vanguard Group Inc. cut its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 17.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,517,325 shares of the biotechnology company's stock after selling 326,415 shares during the quarter. Vanguard Group Inc. owned about 5.13% of AnaptysBio worth $28,207,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ANAB. Barclays PLC increased its holdings in shares of AnaptysBio by 88.6% during the 4th quarter. Barclays PLC now owns 83,567 shares of the biotechnology company's stock worth $1,107,000 after acquiring an additional 39,267 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 1,531 shares during the last quarter. Nebula Research & Development LLC acquired a new position in AnaptysBio in the 4th quarter valued at $231,000. Susquehanna Fundamental Investments LLC acquired a new position in AnaptysBio in the 4th quarter valued at $593,000. Finally, Northern Trust Corp grew its holdings in AnaptysBio by 10.0% in the 4th quarter. Northern Trust Corp now owns 219,986 shares of the biotechnology company's stock valued at $2,913,000 after buying an additional 20,073 shares in the last quarter.

AnaptysBio Stock Up 1.4%

Shares of ANAB traded up $0.28 during trading hours on Tuesday, hitting $20.61. 188,250 shares of the company were exchanged, compared to its average volume of 443,568. The company has a market cap of $577.08 million, a price-to-earnings ratio of -4.60 and a beta of -0.19. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $40.70. The firm's fifty day moving average is $23.20 and its 200 day moving average is $20.89.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.16. The company had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. Analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In related news, Director Hollings Renton sold 20,925 shares of the company's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director directly owned 4,965 shares in the company, valued at $117,025.05. This represents a 80.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 33.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on ANAB shares. JPMorgan Chase & Co. upped their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Wedbush upped their price objective on AnaptysBio from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Guggenheim reaffirmed a "buy" rating and issued a $90.00 price objective (up from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. UBS Group reaffirmed a "neutral" rating and issued a $20.00 price objective (up from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. Finally, HC Wainwright raised AnaptysBio from a "neutral" rating to a "buy" rating and upped their price objective for the company from $22.00 to $38.00 in a report on Wednesday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $46.13.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.